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Abstract
Background: Bread is an important component of the diet in many countries and provides needed nutrients but
also typically too much of other nutrients e.g., sodium. We therefore aimed to use linear programing to determine
the optimal design of low-cost “heart healthy bread” (HHB) and to compare the results with commercial breads in
15 countries.
Methods: Optimization using linear programing focused on achieving set loaf prices (at NZ$1.5 and $3) and for a
range of minimal sodium levels. Then within those constraints, levels of alpha-linolenic acid (ALA) were maximized,
then dietary fiber, and then polyunsaturated fatty acids. Data from New Zealand (NZ) was used for the HHB designs
and comparison nutrient and price data came from breads in 15 high-income countries.
Results: The optimized loaf costing NZ$1.50 in ingredients (HHB$1.5) was superior to the commercial white loafs in
three out of the eight heart health nutrient categories. The optimized loaf that was high in linseed and cost NZ$3
in ingredients (HHB$3), was nutritionally superior to the commercial loafs with seeds/nuts in six out of the eight
heart health categories (i.e., in terms of sodium, potassium, fatty acid ratio and fiber). In terms of value-per-weight, a
commercial white loaf from the UK was slightly cheaper than the HHB$1.50 loaf (at US$0.07 vs US$0.10 per 100 g
loaf). But compared to the other seed/nut loafs, the HHB$3 loaf was the best value at US$0.17 per 100 g, vs a mean
of US$0.85 per 100 g across international comparators.
Conclusions: This proof-of-concept study suggests it is possible to design breads that are nutritionally superior to
commercially available breads from a heart health perspective, as well as being lower cost. Such HHB designs could
be promoted by health agencies and utilized in conjunction with a government-funded bread voucher system for
those at high risk of cardiovascular disease.
Keywords: Cardiovascular disease, Bread design, Linear programing, Optimization, Sodium, Fiber, Alpha-linolenic
acid, Saturated fat
Background
The global burden of non-communicable diseases
(NCDs) accounted for two of every three deaths (34.5
million) worldwide in 2010 [1]. Furthermore, a global es-
timate for 2013 indicated the high burdens of years lived
with disability from: diabetes (29.5 million), cardiovascu-
lar disease (21.2 million) and cancer (6.7 million) [2].
Dietary risk factors are particularly important for
NCDs such as cardiovascular disease (CVD) [3] and
these include dietary intakes of sodium, fiber and types
of fatty acids. One food which has all three of these nu-
trients is bread. It is also one of the most popular foods
in many developed countries e.g., 8.7 % of total energy
in the United States, albeit the combined category of
“bread, rolls and crackers” [4]. Even more so in Canada,
“refined breads” contributed more dietary energy than
all the other food groups in those aged 18 to 65 years
(range by age/sex groups: 10.5 to 11.8 %), with whole-
grain breads contributing another few percent (range:
2.4 to 4.1 %) [5]. For men in the United Kingdom, white
bread was the second highest non-beverage food in
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those aged 19–64 years (by weight with a median of 46 g
per day; interquartile range [IQR]: 18–93) after vegeta-
bles [6]. But for women it was less at a median of 27 g
per day (IQR: 9–61).
Based on commercial varieties of bread available, there
appears to be substantial flexibility around the levels of
the main ingredients (e.g., flour, yeast, salt) and also add-
itional ingredients such as nuts and seeds. For example,
a number of European governments aim to reduce so-
dium intakes by regulating the maximal level of sodium
in bread [7, 8]. This action is supported by various mod-
eling studies that suggest both health and economic
advantages of reducing sodium in bread (e.g., for
Argentina [9–11], Australia [12, 13], New Zealand [14]
and South Africa [15]). Furthermore, there have been
successful studies and interventions to replace sodium
chloride in bread with potassium salts [16–18].
But other aspects of bread design can also be consid-
ered from a CVD prevention perspective given the evi-
dence from systematic reviews around: increasing
dietary fiber [19, 20] and increasing linseed (flaxseed) in-
take which is high in alpha-linolenic acid [21, 22]. Yet
despite this evidence, our examination of the literature
(as of June 2015) identified no optimization studies spe-
cifically relating to the design of heart healthy bread,
and none concerning the design of low-cost healthier
bread.
So to further progress thinking around this issue, we
aimed to design optimized versions of low-cost “heart
healthy breads” (HHBs). Our specific major aim was to
determine, at a “proof-of-concept” level, if it was pos-
sible to design breads that had both improved nutrient
levels from a CVD prevention perspective and which
were relatively low-cost. Our secondary aims were: (i) to
determine how these HHBs compared with commercial
breads in 15 high-income countries; and (ii) to estimate
the cost of mass production of HHB loafs using
publicly-available data for the cost-structure data of
bread manufacture.
We specifically aimed to use linear programing in our
methods as this is an established tool in studying the
optimization of food and diets where there are multiple
nutritional and other objectives [23]. It has also been
used previous around bread in diets e.g., for studying so-
dium and iodine in the diets of Indigenous Australians
[24], for the inclusion of wholemeal bread in food aid in
France [25], and for changing bread intake as part of im-
proving nutrient intakes for the Italian population [26].
Methods
While more detailed steps follow, in summary this work
began with literature searches for identifying potential
bread ingredients and their nutritional value from a
CVD prevention perspective. This was then followed by
a determination of the specific nutrient constraints to be
applied and optimization priorities set, for the analysis
using linear programing. New Zealand nutrient and
price data were used for the HHB designs and data for
comparison with commercial breads were obtained for
15 high-income (OECD) countries from freely accessible
nutrient databases that could be identified online.
Publicly-available data for the cost-structure of bread
manufacture from the Canadian baking industry was
then used to better estimate the cost of mass production
of HHB loafs.
Potential ingredients considered for bread designs
We considered the following potential bread ingredients
from a CVD prevention perspective, based on how key
bread components are described in the literature:
 A high potassium salt substitute, as this type of salt
has been associated with blood pressure reduction in
a meta-analysis [27]. There is also evidence that
potassium chloride can achieve flavor compensation
that allows for large reductions in sodium levels in
bread [28].
 Wholemeal flour, given the evidence for reduced
CVD risk as per three systematic reviews [19, 20,
29] and an analysis of two large prospective studies
[30]. Although outside of the CVD perspective, we
note that dietary fiber from whole grains also
appears to protect against colorectal cancer in
another systematic review [31].
 Linseed, as this is high in dietary fiber, lignans and
n-3 polyunsaturated fatty acids (PUFA) and there is
some evidence for CVD-related benefits as per three
reviews [32–34] and a recent trial [35]. More
specifically, two meta-analyses report blood
pressure reduction associated with linseed
consumption [21, 22].
 Walnut (English walnut), as there is evidence that
this food can benefit cardiovascular health as per a
systematic review [36] and another recent review
[37]. Indeed, nut consumption more broadly is
associated with reduced risk of both CVD and
cancer according to a systematic review [38] and a
large cohort study [39]. Given this we also considered
the addition of other seeds that are known to be
commonly used in commercial breads, i.e., sesame
seeds, sunflower seeds and pumpkin seeds.
Potential ingredients not included
Plausible healthy bread ingredients from a CVD per-
spective identified in the literature included: soy pro-
tein [40], sourdough [41], and high phenolic olive oil
[42]. But in this initial work we did not include these
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ingredients on the grounds of potentially relatively
lower consumer acceptability.
Constraints and optimization approach used for the linear
programing
Based on the above, the specific details on the constraints
applied and optimization priorities are outlined in Table 1.
To summarize, optimization focused on achieving two set
loaf prices (at NZ$1.5 and $3) and for a range of minimal
sodium levels. Then within those constraints, the first pri-
ority in the “objective function” was to maximize levels of
alpha-linolenic acid (ALA) (an omega-3 fatty acid),
followed by maximizing dietary fiber, and then maximiz-
ing polyunsaturated fatty acids (PUFA).
The simplex algorithm was used to solve these linear
programing problems (see Briend et al. [23] for a
detailed description of the linear programing). The prob-
lem of multiple objectives with priority levels is
addressed with lexicographic goal programing, which in-
volves a sequence of linear programing steps [43]. Most
of the scenarios were modeled in Microsoft Excel 2010
(Excel Solver, Simplex method), but where there was a
high level of complexity with the food combination op-
tions the R programing language was used (version
2.15.0, lpSolve package).
Nutrient and price data for the HHBs
The nutrient data for the HHBs was sourced from a
New Zealand food composition database [44]. But, in
some cases we had to use other sources such as a study
on levels of alpha-linolenic acid covering nuts and seeds
[45] and from the nutrient panel on the packaging (i.e.,
for the salt substitute). For the price data for HHB ingre-
dients, the cheapest retail source for the ingredients
were used, with these typically being supermarkets and
online stores in New Zealand.
Table 1 Constraints and optimization targets for the design of the “heart healthy breads”
Ingredients and nutrients Constraints and optimization targets Further details
Cost and weight
Cost per loaf (ingredient costs
only)
$NZ1.50, $3.00 Set target values for baseline analyses (with the highest value still substantially
less than commercial artisan bread loafs in the current NZ setting in the $NZ8
plus range).
Total weight of dry ingredients 700-800 g Makes around one kg of HHB loaf (given the addition of water to the recipe:
see below).
Required ingredients
Active yeast mixture 3 to 4 tsp (12–16 g) Basic requirement for bread design to ensure the bread rises, with 12 g for
the HHB$1.5 loaf but slightly more (16 g) for the HHB$3 loaf given the
increased weight of the seed ingredients.
White or wholemeal flour ≥550 g Set at 50 % each for white and wholemeal flour for the HHB$1.5 loaf; but at
25 % white and 75 % wholemeal for the HHB$3 loaf (to avoid excessive
density and chewiness).
Water 450 mls added to HHB$1.5
and 500 mls to HHB$3
Evaporation of the water during baking is a determinant of the final loaf weight.
Total weight of added seeds/nuts ≤150 g This was an arbitrary upper limit to constrain bread density and chewiness
(especially relevant for older people and those with suboptimal dentition).
Nevertheless, it is a level still below that found in some commercial breads
e.g., one Finnish bread has 17 % seeds by weight (“Fazer Alku Jyväpala”).
Ground linseed was used rather than whole linseed, given data on
bioavailability and gastrointestinal tolerance [56].
Key CVD-related nutrients
Sodium <350 mg/100 g Range for all the dry ingredients collectively (with a goal of <300 mg/100 g
for the cooked loafs). The salt substitute with potassium chloride (KCl) was
the preferred source of sodium (over normal salt) but was limited to a
maximum of 1.5 tsp (9 g) per loaf to avoid any bitterness. The range of 250
to 300 mg/100 g in a final loaf would be substantially less than the mean
level in 2013 in NZ (410 mg/100 g) [57] and for most breads in other high-
income countries e.g., the USA [58].
Alpha-linolenic acid (ALA) Maximize Maximized ahead of fiber and PUFA (first priority of the objective function).
Dietary fiber Maximize Maximized ahead of PUFA (second priority of the objective function).
Polyunsaturated fatty acids
(PUFA)
Maximize Maximized after maximizing fiber and ALA (third priority of the objective function).
Potassium Not specifically optimized Given the use of a KCl containing salt-replacement, we focused on lowering
sodium rather than increasing potassium.
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Country comparisons of commercial breads
For country comparisons we considered just OECD
countries and we conducted internet searches for those
which had online documentation of nutrient profiles on
commercial breads. In particular we used the EuroFIR
database [46] which had 15 freely accessible nutrient da-
tabases. Ultimately, the only OECD countries with such
databases were: Canada, Czech Republic, Denmark,
Finland, Greece, Iceland, Italy, the Netherlands, New
Zealand, Slovakia, Sweden, Switzerland, United States
and the United Kingdom. For these countries the nutri-
ent data on the most standard pre-packaged white bread
was obtained. Only six of these countries had nutrient
data on any breads containing seeds or nuts (Denmark,
Finland, Iceland, Netherlands, New Zealand and
Switzerland). Where there were multiple such breads,
the one with the highest level of PUFA was selected as
a proxy for the highest level of seeds/nuts.
Bread price information was sourced from online su-
permarkets in each country. At first, an attempt to iden-
tifying the largest supermarket chain in each country
was made. Failing this, a search of the online supermar-
kets in the capital city was performed. Out of the breads
marketed in these online supermarkets, the lowest
priced most standard white pre-packaged loaf was se-
lected for price information. For breads with seeds/nuts,
the price data was from the one with the highest seed/
nut level (based on the ingredient listing). For all the
prices we calculated cost per 100 g and cost per 1000 kJ
in US dollars using OECD exchange rates and pur-
chasing power parity adjustments [47]. For specific
nutrient and price methods details for each country
see Additional file 1.
Estimating mass production costs of HHBs
To estimate the cost of mass production of HHB loafs,
publicly-available data for the cost-structure data of
bread manufacture from the Canadian baking industry
was used. Such data are not readily available in other
countries (including New Zealand), presumably due to
reasons of commercial sensitivity. This Canadian cost-
structure covered: “materials and supplies”, “energy,
water and vehicle fuel” and “production worker wages”
[48]. We applied this to the cost of the cheapest super-
market white bread from New Zealand (NZ$1.00 or
US$0.68 for a 600 g loaf ) and assumed at this price it
was basically “cost price” i.e., with no profit. Using rec-
ipes for a white loaf of bread [49], we then estimated
how much more cheaply the ingredients for this com-
mercial bread might typically cost the baking industry,
compared to ingredient prices in the supermarket. This
scalar was then applied to all the HHB ingredients and
varying levels of profit margin were also considered (for
the manufacturer and retailer). We assumed HHBs
would be mass produced by existing bread manufac-
turers with existing plant and machinery and distribu-
tion networks. Further details on the methods are shown
with the tabulated results.
Results
Optimized HHB ingredient selection
The optimized HHB$1.5 loaf was characterized by hav-
ing some wholemeal flour but the cost constraint re-
sulted in only trivial levels of added seeds (Table 2,
Fig. 1). The optimized HHB$3 loaf (Fig. 1) had up to the
maximum weight of seeds permitted (150 g dry ingredi-
ents per loaf, 12.6 % of the final loaf weight). But linseed
Table 2 Dry ingredients of the two optimized “heart healthy breads” per 100 g of dry ingredient weight
HHB$1.5 HHB$3
Quantity of dry ingredients (g) Percentage of dry ingredients Quantity of dry ingredients (g) Percentage of dry ingredients
Wholemeal flour 334 48 % 464 58 %
White flour 334 48 % 155 19 %
Yeast 12 2 % 16 2 %
Normal salt 8 1 % 7 1 %
Salt substitute 8 1 % 9 1 %
Nuts and seeds
Linseeds 4 1 % 132 16 %
Walnuts 0 0 % 18 2 %
Sunflower seeds 0 0 % 1 0 %
Pumpkin seeds 0 0 % 0 0 %
Sesame seeds 0 0 % 0 0 %
Totals
All dry ingredients 700 100 % 800 100 %
All nuts and seeds 4 1 % 150 19 %
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dominated over walnut and other seeds due to it being a
low-cost source of ALA.
Heart health and other nutrients in the loafs
In indicative rankings, the HHB$1.5 loaf appeared to be
superior to the commercial white loafs from the 15
high-income countries in three out of the eight heart
health nutrient categories (Table 3, Fig. 2). That is, lower
in sodium, and higher in potassium and the ratio of po-
tassium to sodium. It ranked relatively highly in terms of
lower saturated fatty acids (SFA) and a high PUFA/SFA
ratio.
The HHB$3 loaf appeared to be nutritionally superior
to the commercial loafs with seeds/nuts from six coun-
tries in six out of the eight heart health categories
(Table 3, Fig. 2). While it had the best PUFA/SFA ratio,
it did not have the highest levels of PUFA and lowest
levels of SFA. It also appeared superior to the HHB$1.5
loaf in all eight heart health categories except for low
saturated fat. Some of the differences were relatively
large, such as the ALA level in the HHB$3 loaf being 26
times the median for the white loafs and 2.2 times the
median for the commercial high seed/nut loafs.
In terms of other nutrients, the HHB$1.5 bread ap-
peared to perform better than most commercial white
breads (e.g., highest in iodide and zinc) (Table 3). But it
was competing with some breads which were fortified
with calcium, folate and iron. However, relative to the
commercial seed breads, the HHB$3 loaf was in the top
two rankings for: calcium, folate, iodide, iron, low
sugars, and low energy density.
In terms of value-per-weight, a commercial white loaf
from the UK was slightly cheaper than the HHB$1.50
loaf (at US$0.07 vs US$0.10 per 100 g loaf, Table 3). The
HHB$1.5 loaf also performed relatively well in terms of
price per kJ of food energy (fourth equal). But compared
to the other seed/nut loafs, the HHB$3 loaf was by far
the best value-per-weight at US$0.17 vs a mean of
US$0.85 per 100 g.
Possible mass production costs of HHB loafs
From the documented cost-structure of the Canadian
baking industry, we estimated that the New Zealand
baking industry might be obtaining bread ingredients at
around 72 % of supermarket prices that we used in cost-
ing the HHB loafs in the preceding analyses. We used
this percentage to estimate that mass production of
HHB (at zero profit) would be likely to reduce the cost
of the various loafs to: US$0.99 for the HHB$1.5 loaf,
and to US$1.75 for the HHB$3 loaf (Table 4). Such costs
might approximate production costs for a non-profit in-
stitution such as a hospital kitchen with its own bakery.
Where commercial manufacturers/retailers produced
and sold HHB loafs (e.g., as per contracts for a govern-
ment voucher system for provision of HHB) a profit
margin would be relevant (Table 4). For example, a 25 %
profit margin shared by producers and retailers would
push up the price to: US$1.24 for the HHB$1.5 loaf and
US$2.19 for the HHB$3 loaf (Table 4). Based on these
estimates and a 25 % profit mark-up, the HHB$1.5 loaf
at US$0.12 per 100 g would remain well under half that
of the median for the commercial white loafs from the
15 high-income countries in Table 3. Likewise the
HHB$3 loaf at this mark-up would still be the lowest
cost per 100 g out of the seed/nut loafs in Table 3.
Discussion
Main findings and interpretation
This proof-of-concept work generated two potential
HHB designs which were generally superior to commer-
cial breads from 15 high-income (OECD) countries from
a nutrient/CVD prevention perspective (i.e., in terms of
sodium, potassium, fatty acid ratios and dietary fiber).
The higher levels in the HHB$3 bread were often sub-
stantial e.g., 26 times the median ALA level of the white
loafs. Furthermore, in principle the higher fiber levels in
the HHBs could contribute to non-CVD benefits such as
colorectal cancer prevention [31]. Similarly, the walnut
in the HHB$3 loaf could potentially contribute in a
small way to cancer prevention [38, 39], but obviously a
diet designed to minimize cancer risk has many other
aspects such as being high in fruit and vegetables.
Of relevance to food security, the HHB$1.5 loaf was
better value-per-weight than all but one of the commer-
cial white loafs from the 15 countries. The HHB$3 also
outperformed all the seed/nut loafs at a fifth the cost per
100 g of the average. Furthermore, the relatively higher
level of dietary fiber in the HHB loafs might mean they
also provide better value in terms of inducing satiety.
Fig. 1 The loaf on the left is the optimized HHB$1.5 loaf. The loaf in
the middle is the optimized HHB$3 loaf which is high in ground
linseed. The loaf on the right is one that is high in walnut (but which
was subsequently excluded from further study due to its relatively high
cost at NZ$5). (Photography: Pascale Otis)
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Such a satiety benefit has been reported in a study on
wholegrain vs refined bread [50], but not in one of nut-
enriched bread vs nut-free bread [51].
The mass production cost estimates (Table 4) suggest
it would be feasible to produce the HHB$3 loaf in a
place like a hospital kitchen at around US$1.75 per loaf.
The voucher costs for government for this type of loaf
might be US$2.19 per loaf when assuming a 25 % mark-
up by the contracted manufacturer and retailers (or
US$2.63 if a 50 % mark-up is assumed). At two loafs a
week per person (e.g., for a patient at high risk of CVD)
this would be US$274 per year in voucher costs for a
100 % subsidized loaf supply (albeit not including the
voucher delivery and other administration costs).
Whether this is justified from a funder perspective
would depend on many issues such as the priority given
to protecting public health and the health economics
(e.g., the cost-effectiveness of such a program should
ideally be modeled before any implementation).
Study strengths and limitations
This study was, to our knowledge, the first to study the
issue of the optimized design of bread from a heart
health and a low-cost perspective using linear program-
ing. We consider that the constraints imposed, and the
typical ingredients used, will help ensure that such de-
signs have at least some acceptability in high-income
countries where there is often a majority of adults who
Table 3 Comparisons of the nutrient levels of the “heart healthy bread” loafs with commercial breads (nutrients and costs, all values
per 100 g unless indicated otherwise)
Nutrient/cost component White breads
(n = 15 countries)
HHB$1.5 Rank of HHB$1.5a Breads with seeds/
nuts (n = 6 countries)
HHB$3 Rank of HHB$3a
Median IQR Median IQR
Eight heart health relevant characteristicsb
Alpha-linolenic acid (ALA) 0.10 0.05 – 0.17 0.08 6/8 1.19 0.64 – 1.44 2.62 1/3
Total polyunsaturated fatty acids (PUFA) (g) 0.66 0.51 – 1.33 0.52 10=/14 4.52 2.98 – 5.73 4.19 4/6
Total saturated fatty acids (SFA) (g) 0.40 0.29 – 0.70 0.14 2/13 1.25 0.89 – 1.83 0.62 5/6
Ratio PUFA/SFA 2.1 1.7 – 2.5 3.7 3/13 4.4 3.0 – 4.7 6.8 1/6
Sodium (mg) 498 457 – 528 309 1/15 464 437 – 472 231 1/6
Potassium (mg) 130 115 – 157 561 1/15 220 195 – 277 647 1/6
Ratio of potassium to sodium 0.3 0.2 – 0.3 1.8 1/15 0.5 0.4 – 0.6 2.8 1/6
Dietary fiber (g) 3.1 2.6 – 4.3 4.8 4/15 5.2 4.3 – 5.4 8.1 1/6
Other micronutrients
Calcium (mg) 97 54 – 110 23 14/15 40 37 – 43 51 2/6
Folate (mcg) (including synthetic forms
in some fortified white breads)
30 27 – 41 65 3/12 52 44 – 57 83 2/6
Iodide (mcg) 3.8 1.2 – 6.0 40.0 1/8 5.3 3.1 – 16.2 29.6 2/6
Iron (mg) 1.6 1.1 – 2.5 2.2 5/14 1.7 1.4 – 2.7 2.8 2/6
Selenium (mcg) 5.8 2.6 – 14.3 3.0 8/10 5.2 4.1 – 8.0 6.4 3/6
Zinc (mg) 0.8 0.7 – 1.0 1.4 1=/13 1.4 1.1 – 1.9 1.9 3/6
Selected other macronutrients
Dietary energy (kJ) 1047 1026 – 1169 951 2/14 (if low is best) 1188 1168 – 1291 1036 2/5 (if low is best)
Protein (g) 8.4 8.3 – 9.1 7.4 14/15 10.6 9.5 – 11.6 8.8 6/6
Sugars (total) (g) 3.5 1.7 – 4.8 0.5 2/10 2.2 1.45 – 3.4 0.6 2/5
Cost (relevant to food security)c
Cost per 100 g of loaf (US$) 0.28 0.21 – 0.34 0.10 2/15 0.73 0.64 – 0.95 0.17 1/5
Cost per 1000 kJ of food energy (US$) 0.17 0.12 – 0.20 0.11 4=/14 0.34 0.33 – 0.38 0.20 2/5
aIndicative rank in terms of the best values from a health perspective and food security perspective (some of these ranks could change with a larger sample of
comparison breads). From an energy security perspective, low cost per kJ is best. But in terms of weight control, low kJ per 100 g (low energy density) is probably
best. Of note is that the nutrient data in some of the national databases had some gaps e.g., for ALA and iodide (both only 8 of the 15 databases for white bread)
bSome of these nutrient characteristics overlap to some extent (e.g., the two ratios reflect the amounts of the two relevant components)
cHHB costing based on supermarket prices for ingredients and no other production costs. See Table 4 for more details on possible mass production costs
For specific nutrient and price methods details for each country see Supplementary Information
IQR interquartile range
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currently consume at least a light-grained bread (e.g., as
per New Zealand [52]). Indeed, some countries currently
have seed/nut breads sold commercially at up to 17 %
seeds by weight (for Finland, see Table 1).
Nevertheless, this was still just a proof-of-concept
study which only considered two potential designs of
HHB. Indeed, the full “design-universe” of such potential
breads is large and might include other relatively healthy
additional ingredients such as: soy, sourdough, dried
fruit, high phenolic olive oil, and extra fiber sources
(e.g., wheat bran and rye flour), (see the Methods). A ver-
sion particularly suitable for women of child-bearing age
could also include added folic acid for preventing neural
tube defects.
A further limitation was the relatively simplistic nature
of our cost estimates for mass production of the two
HHB designs. Nevertheless, it is plausible that the cost-
structure of Canadian bread manufacture is not
markedly different from other high-income countries.
Our costing estimates also didn’t consider administrative
costs associated with setting up and running any HHB
voucher system (e.g., for people with CVD risk factors).
It also did not consider the environmental impact, as per
Swedish work on emissions of oxides of carbon, sulfur
and nitrogen from bread production [53]. Finally, we did
not explore various other complexities with bringing any
HHB to market. For example, consumer taste testing
would be required (see below), and packaging would
need to be designed. For example, packaging would
probably need to display potassium levels to help people
with renal disease or on particular medication such as
diuretics to avoid excessive intake.
Implications for further research and policy
Consumer testing prior to mass production of any HHB
could be done by a commercial bread manufacturer as
Fig. 2 Levels of potassium and sodium in white bread loafs from 15 countries compared to the two “optimized” heart healthy bread (HHB) designs
Table 4 Estimated mass production costs for “heart healthy bread” designsa
Components Commercial white loaf in NZ HHB$1.5 loaf HHB$3 loaf
NZ$ % NZ$ (US$) % NZ$ (US$) %
Food ingredients 0.70 70 1.15 79 2.27 88
Packaging 0.01 1 0.01 1 0.01 1
Production wages 0.24 24 0.24 16 0.24 9
Vehicle fuel costs, energy and water 0.05 5 0.05 3 0.05 2
Total 1.00 100 1.46 (0.99) 100 2.57 (1.75) 100
Total price after profit mark-up of 10 % 1.60 (1.09) 2.83 (1.93)
– of 25 % mark-up 1.82 (1.24) 3.21 (2.19)
– of 50 % mark-up 2.19 (1.49) 3.86 (2.63)
Loaf weight (g) – average 600 1036 1190
– range 1004 to 1057 1184 to 1195
Price NZ$/100 g at 25 % mark-up (US$) 0.18 (0.12) 0.27 (0.18)
a Relatively simple cost-structure based on the Canadian baking industry [48] and this was used to estimate the ability of the NZ baking industry to obtain cheaper
ingredients relative to the supermarket prices used in the earlier HHB analyses (see Methods). All the prices shown are inclusive of a NZ sales tax (GST) of 15 %.
For this analysis we assumed HHBs would be mass produced by existing bread manufacturers with existing plant and machinery and distribution networks
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part of their routine product development processes.
Similarly, an institution such as a public hospital could
“market test” the acceptability of various HHBs on staff
in a hospital cafeteria. The latter could be done in con-
junction with health orientated non-governmental orga-
nizations which exist in many countries and sometimes
have “endorsement label programs” for heart healthy
foods (e.g., as in New Zealand [54]). If there were con-
cerns about public acceptability of bread design, then a
more incremental approach could involve slowly phasing
down the levels of white flour and sodium while phasing
up the levels of linseed and salt substitute in the HHBs
promoted for mass consumption. Final bread products
could also be considered in terms of the health claims
that could be justifiably made on HHB packaging or
in marketing about these being “functional foods”.
Many countries have rules around such claims with
one example being the European Food Safety Author-
ity’s process for European Union countries [55].
Epidemiological and economic modeling should also
attempt to quantify the effectiveness (in quality-
adjusted life-years gained) and cost-effectiveness of a
government-run voucher system for a HHB version
for those at increased CVD risk (and even for those
at increased risk of cancer given the extra fiber and
seeds in the HHB$3 loaf ).
Conclusions
This proof-of-concept study suggests it is possible to
design breads that are nutritionally far superior from
a heart health perspective to commercially available
breads as well as being lower cost. Such HHB designs
could be utilized in conjunction with a government-
funded voucher system for those at high risk of CVD.
This could be one (albeit small) part of comprehen-
sive CVD prevention programs which ideally should
cover multiple nutritional and physical activity
interventions.
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